In our evolving health care system, dermatologists are increasingly being asked to prove the value of care they provide to patients with severe skin diseases. Current quality measures for inflammatory dermatoses have limited validity and feasibility. Through collaboration and a modified Delphi process, International Dermatology Outcome Measures and the American Academy of Dermatology sought to reach consensus on a valid and feasible provider-assessed global disease severity metric to be incorporated into a quality measure for inflammatory dermatoses. To inform the modified Delphi process, a review of the literature was performed, and data were collected on current provider-assessed global disease severity metrics. After literature review, 36 members of International Dermatology Outcome Measures and the American Academy of Dermatology participated in the modified Delphi process to reach consensus on features of the metric. Psoriasis, atopic dermatitis, and acne achieved overwhelming consensus for inflammatory dermatoses that could be measured in a global disease severity metric. Consensus was also reached on the use of a 5-point ordinal scale with descriptors provided through referenced electronic platforms. Expert development of quality measures incorporating this metric and its inclusion in data collection platforms are critical to enabling dermatologists to prove the value of care provided to patients with severe inflammatory dermatoses.Le texte complet de cet article est disponible en PDF.
Key words : acne, atopic dermatitis, IDEOM, inflammatory dermatoses, quality of care, quality measure, psoriasis
| International Dermatology Outcome Measures has provided financial support for this initiative.
| Dr Gottlieb is a consultant, advisor, and/or speaker for Janssen Inc, Celgene Corp, Bristol Myers Squibb Co, Beiersdorf Inc, Abbvie, UCB, Novartis, Incyte, Lilly, Reddy Labs, Valeant, Demira, Allergan, and Sun Pharmaceutical Industries. Dr Gottlieb has also received research/educational grants from Janssen, Incyte, UCB, Novartis, and Lilly. Ms Salame is the International Dermatology Outcome Measures Research Fellow and receives salary and research support. Dr Armstrong has served as an investigator, consultant, advisor, and/or speaker to AbbVie, Janssen, Lilly, Novartis, Sanofi, Regeneron, Leo, Science 37, Modmed, Pfizer, Ortho Dermatologics, and Modernizing Medicine. Dr Merola has served as a consultant and/or investigator for Biogen IDEC, AbbVie, Eli Lilly, Novartis, Pfizer, Janssen, UCB, Samumed, Science 37, Celgene, Sanofi, Regeneron, Merck and GSK. Dr Takeshita has received a research grant from Pfizer Inc (to the Trustees of the University of Pennsylvania) and payment for continuing medical education work related to psoriasis that was supported indirectly by Eli Lilly and Novartis. Dr Chen has served as site investigator for Incyte and Genentech, received research and educational grants from Pfizer, and consulted for Leo Pharma. Dr Chen also receives royalties from pharma licensure of quality of life instruments. Mr Latella is a Patient Consultant for Boehringer Ingelheim and GsF. Drs Van Beek and Parra have no conflicts of interest to declare.
| Reprints not available from the authors.